JP2018522008A5 - - Google Patents

Download PDF

Info

Publication number
JP2018522008A5
JP2018522008A5 JP2018501178A JP2018501178A JP2018522008A5 JP 2018522008 A5 JP2018522008 A5 JP 2018522008A5 JP 2018501178 A JP2018501178 A JP 2018501178A JP 2018501178 A JP2018501178 A JP 2018501178A JP 2018522008 A5 JP2018522008 A5 JP 2018522008A5
Authority
JP
Japan
Prior art keywords
phe
pen
nal
seq
aminoethoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018501178A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018522008A (ja
JP6858174B2 (ja
Filing date
Publication date
Priority claimed from US14/800,627 external-priority patent/US9624268B2/en
Application filed filed Critical
Priority claimed from PCT/US2016/042680 external-priority patent/WO2017011820A2/en
Publication of JP2018522008A publication Critical patent/JP2018522008A/ja
Publication of JP2018522008A5 publication Critical patent/JP2018522008A5/ja
Application granted granted Critical
Publication of JP6858174B2 publication Critical patent/JP6858174B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018501178A 2015-07-15 2016-07-15 インターロイキン23受容体のペプチド阻害剤、および炎症性疾患を処置するためのそれらの使用 Active JP6858174B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
USPCT/US2015/040658 2015-07-15
US14/800,627 US9624268B2 (en) 2014-07-17 2015-07-15 Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
US14/800,627 2015-07-15
PCT/US2015/040658 WO2016011208A1 (en) 2014-07-17 2015-07-15 Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
US201562264820P 2015-12-08 2015-12-08
US62/264,820 2015-12-08
US201662281123P 2016-01-20 2016-01-20
US62/281,123 2016-01-20
PCT/US2016/042680 WO2017011820A2 (en) 2015-07-15 2016-07-15 Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases

Publications (3)

Publication Number Publication Date
JP2018522008A JP2018522008A (ja) 2018-08-09
JP2018522008A5 true JP2018522008A5 (enExample) 2020-07-30
JP6858174B2 JP6858174B2 (ja) 2021-04-14

Family

ID=57757647

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018501178A Active JP6858174B2 (ja) 2015-07-15 2016-07-15 インターロイキン23受容体のペプチド阻害剤、および炎症性疾患を処置するためのそれらの使用

Country Status (23)

Country Link
EP (1) EP3341011A4 (enExample)
JP (1) JP6858174B2 (enExample)
KR (1) KR102513978B1 (enExample)
CN (1) CN108348580B (enExample)
AU (1) AU2016293619B2 (enExample)
BR (1) BR112018000691A2 (enExample)
CA (1) CA2991984A1 (enExample)
CL (3) CL2018000128A1 (enExample)
CO (1) CO2018000349A2 (enExample)
CR (1) CR20180029A (enExample)
DO (1) DOP2018000010A (enExample)
EA (1) EA035733B9 (enExample)
EC (1) ECSP18002929A (enExample)
HK (1) HK1257747A1 (enExample)
IL (1) IL256827A (enExample)
MX (1) MX384213B (enExample)
NI (1) NI201800008A (enExample)
PE (1) PE20180571A1 (enExample)
PH (1) PH12018500086A1 (enExample)
SG (1) SG10201912066SA (enExample)
SV (1) SV2018005614A (enExample)
UA (1) UA123772C2 (enExample)
WO (1) WO2017011820A2 (enExample)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS58514B1 (sr) 2012-06-13 2019-04-30 Incyte Holdings Corp Supstituisana triciklična jedinjenja kao inhibitori fgfr
EP4091624A1 (en) 2013-03-15 2022-11-23 Protagonist Therapeutics, Inc. Hepcidin analogues and uses thereof
PH12015502383B1 (en) 2013-04-19 2023-02-03 Incyte Holdings Corp Bicyclic heterocycles as fgfr inhibitors
HRP20211448T1 (hr) 2014-05-16 2021-12-24 Protagonist Therapeutics, Inc. Alfa4beta7 integrin tioeter peptidni antagonisti
CN107206254B (zh) 2014-07-17 2021-08-24 领导医疗有限公司 白细胞介素-23受体的口服肽抑制剂以及其治疗炎症性肠病的用途
WO2016054411A1 (en) 2014-10-01 2016-04-07 Protagonist Therapeutics, Inc. NOVEL α4β7 PEPTIDE MONOMER AND DIMER ANTAGONISTS
US10301371B2 (en) 2014-10-01 2019-05-28 Protagonist Therapeutics, Inc. Cyclic monomer and dimer peptides having integrin antagonist activity
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
TWI712601B (zh) 2015-02-20 2020-12-11 美商英塞特公司 作為fgfr抑制劑之雙環雜環
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US10787490B2 (en) 2015-07-15 2020-09-29 Protaganist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
GB2545898B (en) 2015-12-21 2019-10-09 Sutura Therapeutics Ltd Improved drug delivery by conjugating oligonucleotides to stitched/stapled peptides
US20190002503A1 (en) 2015-12-30 2019-01-03 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
CA3017926C (en) 2016-03-23 2023-10-10 Protagonist Therapeutics, Inc. Methods for synthesizing .alpha.4.beta.7 peptide antagonists
WO2018136646A1 (en) 2017-01-18 2018-07-26 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
GB2563875B (en) * 2017-06-28 2020-08-19 Sutura Therapeutics Ltd Improvements in drug delivery
EP3681900A4 (en) 2017-09-11 2021-09-08 Protagonist Therapeutics, Inc. OPIOID AGONIST PEPTIDES AND THEIR USES
CA3089868A1 (en) 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
HRP20241288T1 (hr) 2018-05-04 2024-12-06 Incyte Corporation Čvrsti oblici fgfr inhibitora i postupci za njihovu proizvodnju
AU2019262579B2 (en) 2018-05-04 2024-09-12 Incyte Corporation Salts of an FGFR inhibitor
WO2020014646A1 (en) * 2018-07-12 2020-01-16 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
CN110015978B (zh) * 2019-04-29 2021-03-19 康化(上海)新药研发有限公司 O-[2-[[叔丁氧羰基]氨基]乙基]-n-[芴甲氧羰基]-l-酪氨酸的合成方法
US20220251185A1 (en) * 2019-07-01 2022-08-11 Valitor, Inc. Hydrophilic linkers for multivalent peptide conjugates
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
JP7534382B2 (ja) * 2019-07-10 2024-08-14 プロタゴニスト セラピューティクス, インコーポレイテッド インターロイキン-23受容体のペプチド阻害剤及び炎症性疾患を治療するためのその使用
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CA3157361A1 (en) 2019-10-14 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
EP3819307A1 (en) * 2019-11-07 2021-05-12 CytoKi Pharma ApS Therapeutic derivatives of interleukin-22
JP7832891B2 (ja) 2019-12-04 2026-03-18 インサイト・コーポレイション Fgfr阻害剤の誘導体
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
CA3167751A1 (en) 2020-01-15 2021-07-22 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
AU2021209086A1 (en) * 2020-01-15 2022-08-04 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
AU2021301192A1 (en) * 2020-06-29 2023-02-02 University Of Washington Human IL23 receptor binding polypeptides
JP2023542867A (ja) 2020-09-11 2023-10-12 グリンプス バイオ, インコーポレイテッド 疾患の検出/診断、病期分類、モニタリング及び処置のための生体外でのプロテアーゼ活性検出
JP7397239B2 (ja) 2020-11-20 2023-12-12 ヤンセン ファーマシューティカ エヌ.ベー. インターロイキン-23受容体のペプチド阻害剤の組成物
JP2023145581A (ja) * 2020-11-20 2023-10-11 ヤンセン ファーマシューティカ エヌ.ベー. インターロイキン-23受容体のペプチド阻害剤の組成物
WO2022221170A1 (en) 2021-04-12 2022-10-20 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
US11939331B2 (en) 2021-06-09 2024-03-26 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
CA3220155A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
EP4370146A4 (en) 2021-07-14 2025-05-21 Janssen Biotech, Inc. Lipidated peptide inhibitors of the interleukin-23 receptor
TW202332683A (zh) * 2021-07-14 2023-08-16 美商健生生物科技公司 介白素-23受體之肽抑制劑
EP4370532A4 (en) * 2021-07-14 2025-09-03 Janssen Biotech Inc BICYCLIC PEPTIDE INHIBITORS OF THE INTERLEUKIN-23 RECEPTOR
AU2022402440A1 (en) 2021-12-01 2024-05-30 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
WO2023172648A2 (en) * 2022-03-09 2023-09-14 Glympse Bio, Inc. Fluorogenic substrates for aminopeptidase detection in biofluids
CN114751962B (zh) * 2022-03-17 2023-11-07 北京大学 订书肽、其制备方法及其制药用途
CA3260606A1 (en) 2022-06-30 2024-01-04 Sanofi NEW PEPTIDES FOR USE AS SELECTIVE IL-23 RECEPTOR ANTAGONISTS
WO2024110477A2 (en) * 2022-11-21 2024-05-30 Janssen Pharmaceutica Nv Synthesis of a cyclic peptide
US20240279281A1 (en) * 2023-01-16 2024-08-22 Janssen Pharmaceutica Nv Peptide Inhibitors of Interleukin-23 Receptor
EP4652180A2 (en) * 2023-01-16 2025-11-26 Janssen Pharmaceutica NV Peptide inhibitors of interleukin-23 receptor
WO2024155551A1 (en) * 2023-01-16 2024-07-25 Janssen Pharmaceutica Nv Polycyclic peptide inhibitors of interleukin-23 receptor
IL322423A (en) 2023-01-31 2025-09-01 Janssen Pharmaceutica Nv Methods for preparing crystalline peptide inhibitors of the interleukin-23 receptor
CN121443624A (zh) * 2023-05-04 2026-01-30 西藏海思科制药有限公司 白介素-23受体的肽抑制剂制备及其用途
EP4471049A1 (en) 2023-06-01 2024-12-04 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
EP4471048A1 (en) 2023-06-01 2024-12-04 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
CN121794283A (zh) 2023-09-08 2026-04-03 赛诺菲 作为选择性il-23受体抑制剂的新型肽
CN121909205A (zh) 2023-09-08 2026-04-21 赛诺菲 作为选择性il-23受体抑制剂的新型肽
WO2026013260A1 (en) 2024-07-12 2026-01-15 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
WO2026057052A1 (zh) * 2024-09-14 2026-03-19 深圳信立泰药业股份有限公司 一种il-23受体抑制剂及其制备方法和用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5942492A (en) * 1996-11-12 1999-08-24 Angstrom Pharmaceuticals, Inc. Cyclic peptides that bind to urokinase-type plasminogen activator receptor
CA2677932A1 (en) 2007-02-15 2008-08-21 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
JP2011501941A (ja) * 2007-07-06 2011-01-20 バロリゼイション エイチエスジェイ, ソシエテ アン コマンディテ Il−23レセプターのアンタゴニストおよびその使用
CA2707840A1 (en) 2007-08-20 2009-02-26 Allozyne, Inc. Amino acid substituted molecules
US10416172B2 (en) 2010-03-31 2019-09-17 Medical Diagnostic Laboratories, Llc Recombinant soluble truncated IL-23 receptor (IL-23R) capable of inhibiting IL-23R-mediated cell signaling
US8946150B2 (en) * 2011-06-14 2015-02-03 Medical Diagnostic Laboratories, LLC. Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
US9169292B2 (en) * 2011-06-14 2015-10-27 Medical Diagnostic Laboratories, Llc Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
US20160235807A1 (en) * 2013-10-09 2016-08-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines
CN107206254B (zh) 2014-07-17 2021-08-24 领导医疗有限公司 白细胞介素-23受体的口服肽抑制剂以及其治疗炎症性肠病的用途

Similar Documents

Publication Publication Date Title
JP2018522008A5 (enExample)
US12478617B2 (en) Lipidated peptide inhibitors of interleukin-23 receptor
US20200199086A1 (en) 1,2,4-Oxadiazole Derivatives as Immunomodulators
US20240409598A1 (en) Peptide inhibitors of interleukin-23 receptor
US20240352073A1 (en) Bicyclic peptide inhibitors of interleukin-23 receptor
JP2020505352A5 (enExample)
BR112020014576A2 (pt) Ligantes peptídicos bicíclicos multiméricos
US20240366538A1 (en) Hepatitis B Antiviral Agents
RU2017105115A (ru) Пептидные ингибиторы рецептора интерлейкина-23 для перорального приема и их применение для лечения воспалительных заболеваний кишечника
JP2017530090A5 (enExample)
JP2016518351A5 (enExample)
TW201127378A (en) Benzimidazole-imidazole derivatives
CN102548558B (zh) 具有Aurora A选择性抑制作用的氨基吡啶衍生物
JP2019503340A5 (enExample)
JP2021502980A5 (enExample)
US8536116B2 (en) Antagonists for diseases induced by cells with high-affinity ELR-CXC chemokine receptor proteins
EP3154563B1 (en) New polypeptide
US20210269482A1 (en) Peptoid-peptide macrocycles, pharmaceutical compositions and methods of using the same
CN103173419A (zh) 抗趋化因子4单克隆抗体、杂交瘤细胞系及应用
WO2019061812A1 (zh) 氨基酸骨架类新型cxcr4拮抗剂及其制备与生物医学应用
JP6438585B2 (ja) ピロロ[2,3−d]ピリミジン化合物又はその塩
WO2013129660A1 (ja) オキシトシン受容体作動および/またはバソプレッシン受容体拮抗剤
WO2025137159A1 (en) Human interleukin (il)-17 cytokine binding peptides
JP2024546758A5 (enExample)
CN121449688A (zh) 白介素-23受体的肽抑制剂及其用途